Yirui Pharma Secures Tens of Millions in Series A+ Financing to Accelerate Development of Small Molecule Innovative Targeted Therapies

VCBeat has learned that recently,Hangzhou Yirui Pharmaceutical Technology Co., Ltd.(hereinafter referred to as “Yirui Pharma”) announced the completion of a financing round led byTaikun FundLead Investor,Beijing Tianfeng Capital、Hangzhou Shenghui InvestmentSecured tens of millions of yuan in Series A+ financing, with co-investment from the fund. The proceeds will be used to accelerate the U.S. Phase II clinical trial of the innovative drug YR-001 for the treatment of autoimmune skin diseases, as well as to support preclinical and early-stage clinical development of the company’s other projects.

Yirui Pharma, established in 2018, is a biotech company dedicated to the research and development of innovative small-molecule targeted therapies. The company is committed to driving source innovation through strategic R&D approaches, including scientifically grounded project selection, cost efficiency, high operational efficiency, and effective risk control. With a focus on independent R&D, Yirui Pharma addresses therapeutic areas such as autoimmune diseases, diabetic complications, and chronic inflammatory disorders. By implementing differentiated strategies in drug target selection, indication prioritization, administration routes, and patient populations, the company strives to provide novel first-line treatments to meet the unmet clinical needs of hundreds of millions of patients worldwide.

Amid the overall downturn in the global economy, investor enthusiasm for biopharmaceuticals plummeted after the second half of 2022. Many investment firms completely exited the biopharmaceutical sector, plunging the entire new drug development field into a “rapid freeze” in financing. The successful completion of this Series A+ round once again demonstrates the market’s recognition and trust in Yirui Pharma’s R&D team and capabilities. This round of investment will provide strong support for the company’s research and development and clinical trials.

Regarding the securing of this round of financing,Dr. Wang Xiaolu, Founder of Yirui Pharmastated: “We extend our sincere gratitude to institutions such as Taikun Fund and Beijing Tianfeng Capital for their trust and support in Yirui Pharma’s innovative R&D capabilities, clinical development expertise, and future commercialization potential. The proceeds from this financing will provide crucial support for the clinical development of our potential first-in-class innovative drugs and the advancement of our new pipeline. Yirui Pharma is currently in a phase of rapid growth, with multiple ongoing research projects at the international forefront. The selected targets have been robustly validated, positioning us as the exclusive or first mover in China, with only a very limited number of companies worldwide developing similar candidates concurrently. We remain committed to delivering superior therapeutic solutions for patients globally, thereby benefiting patients worldwide.”

Guan Jifeng, Founding Partner of Tianfeng CapitalStatement: Yirui Pharma’s R&D team is composed of elite overseas-returnees and senior scientists with many years of experience in innovative drug development. More than a decade ago, while working abroad, our founder, Dr. Wang Xiaolu, facilitated the transfer of China rights for an original overseas potential blockbuster novel drug to a domestic pharmaceutical company. This drug was recently approved by the China National Medical Products Administration (NMPA) for its first global launch in China, breaking the decade-long absence of new innovative drugs in this therapeutic area in the domestic market. It has provided strong support and a successful case study for the transformation, upgrading, and restructuring of China’s pharmaceutical industry. Throughout Yirui’s entrepreneurial journey, our team has gained deep insights into the R&D strategies, industrial chain landscape, and competitive dynamics of the global and Chinese pharmaceutical industries. We excel at designing top-level strategies for innovative drug companies, leveraging China’s globally competitive advantages in the novel drug R&D supply chain to develop world-leading original innovative drugs with lower costs and higher efficiency. We believe that with financial and strategic support from investment institutions, Yirui Pharma will be able to accelerate and enhance its innovative drug R&D process, collaborating with the global and Chinese pharmaceutical industries to jointly drive innovative development in the global healthcare sector.